As always, it was a delight to speak with our Editor-in-Chief, Peter C Taylor (University of Oxford, Oxford, UK). In this interview, we discuss JAK inhibitors and RA-related pain alongside the findings from the FINCH Phase 3 RA clinical trial program of filgotinib. The abstract ‘Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials’ (ABSTRACT NUMBER: 1201) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
1. What are the major unmet needs in terms of pain control in the treatment of rheumatoid arthritis? (0:06)
2. What is the rationale for the use of JAK inhibitors in the treatment of rheumatoid arthritis? (1:49)
3. Could you give us a brief overview of the FINCH clinical studies and the findings? (3.32)
4. Could you tell us about the post-hoc analysis of the FINCH studies data? (4:22)
5. How do you think these findings could impact clinical practice? (10:36)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Rheumatoid Arthritis
Peter Taylor, EULAR 2023: Current perspectives on the selectivity and safety of JAK inhibitors to target the pathophysiology of rheumatoid arthritis
Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]
Jérôme Avouac, EULAR 2023: Effects of B cell depletion by CD19-targeted CAR-T cells in a murine model of systemic sclerosis
touchIMMUNOLOGY spoke with editorial board member Jérôme Avouac (Hôpital Cochin, Paris, France) to discuss his highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of rheumatoid arthritis, and his presentation on the potential of CD19-targeted CAR-T cell transfer for systemic sclerosis. The abstract ‘Effects of B cell depletion by […]
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!